BEOVU

This brand name is authorized in Austria, Canada, Cyprus, Estonia, Finland, Hong Kong, Croatia, Ireland, Israel, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, United Kingdom, United States

Active ingredients

The drug BEOVU contains one active pharmaceutical ingredient (API):

1 Brolucizumab UNII XSZ53G39H5 - BROLUCIZUMAB

Brolucizumab is a humanised monoclonal single chain Fv (scFv) antibody fragment with a molecular weight of ~26 kDa. Increased levels of signalling through the vascular endothelial growth factor A (VEGF-A) pathway are associated with pathological ocular angiogenesis and retinal oedema. Brolucizumab binds with high affinity to VEGF-A isoforms (e.g. VEGF110, VEGF121, and VEGF165), thereby preventing binding of VEGF-A to its receptors VEGFR-1 and VEGFR-2. By inhibiting VEGF-A binding, brolucizumab suppresses endothelial cell proliferation, thereby reducing pathological neovascularisation and decreasing vascular permeability. Read about Brolucizumab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
BEOVU Solution for injection	European Medicines Agency (EU)	MPI, EU: SmPC
BEOVU Solution for injection	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
S01LA06		S Sensory organs → S01 Ophthalmologicals → S01L Ocular vascular disorder agents → S01LA Antineovascularisation agents
Discover more medicines within S01LA06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 02496976
Country: EE	Ravimiamet	Identifier(s): 1811393, 1811405
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 113179
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 381073
Country: HK	Department of Health Drug Office	Identifier(s): 67008, 67009
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 8761
Country: JP	医薬品医療機器総合機構	Identifier(s): 1319406G1024
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1089424, 1089425
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 201790
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 21469, 21470
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100432311
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W66674001
Country: US	FDA, National Drug Code	Identifier(s): 0078-0827